An Open Label, Positron Emission Tomography (PET) Study With [11C]AZ10419369 to Determine Central 5-HT1B Receptor Occupancy of ZOMIG Rapimelt (Zolmitriptan) in Healthy Male Volunteers.

Trial Profile

An Open Label, Positron Emission Tomography (PET) Study With [11C]AZ10419369 to Determine Central 5-HT1B Receptor Occupancy of ZOMIG Rapimelt (Zolmitriptan) in Healthy Male Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2010

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Cluster headache; Migraine
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Nov 2010 Actual patient number (10) added as reported by ClinicalTrials.gov.
    • 18 Oct 2010 Actual end date added to 1 Oct 2010 as reported by ClinicalTrials.gov record.
    • 18 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top